B-intervention	0	5	Omega
I-intervention	5	6	-
I-intervention	6	7	3
I-intervention	8	13	fatty
I-intervention	14	18	acid
O	19	22	use
O	23	26	for
O	27	32	obese
O	33	39	breast
O	40	46	cancer
O	47	55	patients
O	56	60	with
B-condition	61	70	aromatase
I-condition	71	80	inhibitor
I-condition	80	81	-
I-condition	81	88	related
I-condition	89	99	arthralgia
O	100	101	(
O	101	105	SWOG
O	106	111	S0927
O	111	112	)
O	112	113	.

O	114	122	Although
O	123	132	aromatase
O	133	143	inhibitors
O	144	145	(
O	145	148	AIs
O	148	149	)
O	150	157	prolong
O	158	166	survival
O	167	169	in
O	170	174	post
O	174	175	-
O	175	185	menopausal
O	186	192	breast
O	193	199	cancer
O	200	201	(
O	201	203	BC
O	203	204	)
O	205	213	patients
O	213	214	,
O	215	217	AI
O	217	218	-
O	218	228	associated
O	229	239	arthralgia
O	240	243	can
O	244	248	lead
O	249	251	to
O	252	267	discontinuation
O	267	268	.

O	269	274	Obese
O	275	283	patients
O	284	288	have
O	289	295	higher
O	296	301	rates
O	302	304	of
O	305	307	AI
O	308	318	arthralgia
O	319	323	than
O	324	327	non
O	327	328	-
O	328	333	obese
O	334	342	patients
O	342	343	,
O	344	347	but
O	348	357	treatment
O	358	365	options
O	366	369	are
O	370	377	limited
O	377	378	.

O	379	384	Omega
O	384	385	-
O	385	386	3
O	387	392	fatty
O	393	397	acid
O	398	399	(
O	399	401	O3
O	401	402	-
O	402	404	FA
O	404	405	)
O	406	415	treatment
O	416	419	for
O	420	422	AI
O	423	433	arthralgia
O	434	437	has
O	438	446	produced
O	447	452	mixed
O	453	460	results
O	460	461	.

O	462	464	We
O	465	474	performed
O	475	477	an
O	478	489	exploratory
O	490	498	analysis
O	499	501	of
O	502	506	SWOG
O	507	512	S0927
O	512	513	,
O	514	515	a
O	516	527	multicenter
O	528	538	randomized
O	539	546	placebo
O	546	547	-
O	547	557	controlled
O	558	563	trial
O	564	566	of
O	567	569	O3
O	569	570	-
O	570	572	FA
O	573	576	use
O	577	580	for
O	581	583	AI
O	584	594	arthralgia
O	594	595	.

B-eligibility	596	600	Post
I-eligibility	600	601	-
I-eligibility	601	611	menopausal
I-eligibility	612	617	women
I-eligibility	618	622	with
I-eligibility	623	628	stage
I-eligibility	629	630	I
I-eligibility	630	631	-
I-eligibility	631	634	III
I-eligibility	635	637	BC
I-eligibility	638	644	taking
I-eligibility	645	647	an
I-eligibility	648	650	AI
O	651	655	were
O	656	666	randomized
O	667	669	to
O	670	672	24
O	673	678	weeks
O	679	681	of
O	682	684	O3
O	684	685	-
O	685	688	FAs
O	689	691	or
B-control	692	699	placebo
O	699	700	.

O	701	706	Brief
O	707	711	Pain
O	712	721	Inventory
O	722	723	(
O	723	726	BPI
O	726	727	)
O	728	742	questionnaires
O	743	746	and
O	747	754	fasting
O	755	760	serum
O	761	765	were
O	766	775	collected
O	776	778	at
O	779	787	baseline
O	787	788	,
O	789	791	12
O	791	792	,
O	793	796	and
O	797	799	24
O	800	805	weeks
O	805	806	.

O	807	810	The
O	811	814	BPI
O	815	825	assessment
O	826	834	included
O	835	840	worst
O	841	845	pain
O	845	846	,
O	847	854	average
O	855	859	pain
O	859	860	,
O	861	864	and
O	865	869	pain
O	870	882	interference
O	883	889	scores
O	890	891	(
O	891	896	range
O	897	898	0
O	898	899	-
O	899	901	10
O	901	902	)
O	902	903	.

O	904	909	Among
O	910	913	the
B-total-participants	914	917	249
O	918	930	participants
O	930	931	,
O	932	935	139
O	936	939	had
O	940	943	BMI
O	944	945	<
O	946	948	30
O	949	951	kg
O	951	952	/
O	952	954	m2
O	955	956	(
O	956	958	56
O	958	959	%
O	959	960	)
O	961	964	and
O	965	968	110
O	969	972	had
O	973	976	BMI
O	977	978	â‰¥
O	979	981	30
O	982	984	kg
O	984	985	/
O	985	987	m2
O	988	989	(
O	989	991	44
O	991	992	%
O	992	993	)
O	993	994	.

O	995	1000	Among
B-outcome	1001	1006	obese
I-outcome	1007	1015	patients
O	1015	1016	,
O	1017	1019	O3
O	1019	1020	-
O	1020	1022	FA
O	1023	1026	use
O	1027	1030	was
O	1031	1041	associated
O	1042	1046	with
O	1047	1060	significantly
O	1061	1066	lower
B-outcome	1067	1070	BPI
I-outcome	1071	1076	worst
I-outcome	1077	1081	pain
I-outcome	1082	1088	scores
I-outcome	1089	1091	at
I-outcome	1092	1094	24
I-outcome	1095	1100	weeks
O	1101	1109	compared
O	1110	1114	with
O	1115	1122	placebo
O	1123	1124	(
B-iv-cont-mean	1124	1125	4
I-iv-cont-mean	1125	1126	.
I-iv-cont-mean	1126	1128	36
O	1129	1131	vs
O	1131	1132	.
B-cv-cont-mean	1133	1134	5
I-cv-cont-mean	1134	1135	.
I-cv-cont-mean	1135	1137	70
O	1137	1138	,
O	1139	1140	p
O	1141	1142	=
O	1143	1144	0
O	1144	1145	.
O	1145	1147	02
O	1147	1148	)
O	1148	1149	,
O	1150	1157	whereas
O	1158	1163	among
B-outcome	1164	1167	non
I-outcome	1167	1168	-
I-outcome	1168	1173	obese
I-outcome	1174	1182	patients
O	1182	1183	,
O	1184	1189	there
O	1190	1193	was
O	1194	1196	no
O	1197	1208	significant
O	1209	1219	difference
O	1220	1222	in
O	1223	1229	scores
O	1230	1237	between
O	1238	1247	treatment
O	1248	1252	arms
O	1253	1254	(
B-iv-cont-mean	1254	1255	5
I-iv-cont-mean	1255	1256	.
I-iv-cont-mean	1256	1258	27
O	1259	1261	vs
O	1261	1262	.
B-cv-cont-mean	1263	1264	4
I-cv-cont-mean	1264	1265	.
I-cv-cont-mean	1265	1267	58
O	1267	1268	,
O	1269	1270	p
O	1271	1272	=
O	1273	1274	0
O	1274	1275	.
O	1275	1277	28
O	1277	1278	;
O	1279	1290	interaction
O	1291	1292	p
O	1293	1294	=
O	1295	1296	0
O	1296	1297	.
O	1297	1299	05
O	1299	1300	)
O	1300	1301	.

O	1302	1311	Similarly
O	1311	1312	,
O	1313	1315	O3
O	1315	1316	-
O	1316	1318	FA
O	1319	1322	use
O	1323	1326	was
O	1327	1337	associated
O	1338	1342	with
O	1343	1348	lower
B-outcome	1349	1352	BPI
I-outcome	1353	1360	average
I-outcome	1361	1365	pain
O	1366	1369	and
B-outcome	1370	1374	pain
I-outcome	1375	1387	interference
I-outcome	1388	1394	scores
O	1395	1397	at
O	1398	1400	24
O	1401	1406	weeks
O	1407	1415	compared
O	1416	1420	with
O	1421	1428	placebo
O	1429	1434	among
O	1435	1440	obese
O	1441	1449	patients
O	1449	1450	,
O	1451	1454	but
O	1455	1457	no
O	1458	1469	significant
O	1470	1480	difference
O	1481	1488	between
O	1489	1498	treatment
O	1499	1503	arms
O	1504	1506	in
O	1507	1510	non
O	1510	1511	-
O	1511	1516	obese
O	1517	1525	patients
O	1526	1527	(
O	1527	1538	interaction
O	1539	1540	p
O	1541	1542	=
O	1543	1544	0
O	1544	1545	.
O	1545	1548	005
O	1549	1552	and
O	1553	1554	p
O	1555	1556	=
O	1557	1558	0
O	1558	1559	.
O	1559	1561	01
O	1561	1562	,
O	1563	1575	respectively
O	1575	1576	)
O	1576	1577	.

O	1578	1580	In
O	1581	1586	obese
O	1587	1589	BC
O	1590	1598	patients
O	1598	1599	,
O	1600	1602	O3
O	1602	1603	-
O	1603	1605	FA
O	1606	1609	use
O	1610	1613	was
O	1614	1624	associated
O	1625	1629	with
O	1630	1643	significantly
O	1644	1651	reduced
O	1652	1654	AI
O	1655	1665	arthralgia
O	1666	1674	compared
O	1675	1677	to
O	1678	1685	placebo
O	1685	1686	.
